Samsung Biologics Co.,Ltd. (KRX: 207940)

Samsung Biologics Co.,Ltd. Balance Sheet

Financials in millions KRW. Fiscal year is January - December.

Fiscal Year	TTM	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Sep 30, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Cash & Equivalents	540,227	367,937	890,820	47,410	28,850	125,101
Short-Term Investments	447,884	1,688,338	2,204,212	473,985	323,156	354,782
Trading Asset Securities	-	-	98,506	850,040	500,046	210,040
Cash & Short-Term Investments	988,111	2,056,276	3,193,537	1,371,435	852,052	689,923
Cash Growth	-45.63%	-35.61%	132.86%	60.96%	23.50%	-37.72%
Accounts Receivable	-	-	-	0	-	-
Receivables	-	-	-	0	400	-
Inventory	2,686,444	2,641,368	2,375,819	1,012,871	645,960	452,470
Prepaid Expenses	21,247	26,830	23,201	8,579	7,124	5,920
Other Current Assets	1,113,094	797,513	865,099	430,291	245,811	207,949
Total Current Assets	4,808,895	5,521,988	6,457,657	2,823,175	1,751,347	1,356,262
Property, Plant & Equipment	5,149,561	4,342,424	3,871,452	2,227,687	1,760,728	1,718,911
Long-Term Investments	53,396	47,435	38,110	2,661,499	2,634,603	2,652,739
Goodwill	1,677,608	1,677,608	1,677,608	-	-	-
Other Intangible Assets	1,279,487	1,580,423	1,541,850	32,172	23,345	21,828
Long-Term Accounts Receivable	-	0	-0	0	-0	-
Long-Term Deferred Charges	2,723,462	2,574,057	2,741,848	-	-	-
Other Long-Term Assets	333,902	302,236	253,524	225,477	253,879	161,487
Total Assets	16,026,340	16,046,197	16,582,050	7,970,011	6,424,201	5,911,627
Accounts Payable	191,195	208,278	59,616	32,251	54,984	12,290
Accrued Expenses	338,456	281,317	207,437	74,322	64,356	43,876
Short-Term Debt	377,000	654,500	582,783	50,000	30,000	150,000
Current Portion of Long-Term Debt	230,000	733,405	556,017	109,855	160,907	251,650
Current Portion of Leases	138,457	144,031	142,247	7,537	6,533	3,249
Current Income Taxes Payable	281,065	191,212	223,299	110,174	23,260	12,857
Current Unearned Revenue	503,790	399,818	432,680	-	-	-
Other Current Liabilities	1,503,796	1,545,301	1,977,462	723,156	249,261	216,583
Total Current Liabilities	3,563,760	4,157,861	4,181,542	1,107,295	589,301	690,505
Long-Term Debt	214,832	239,783	965,090	1,114,684	571,451	236,167
Long-Term Leases	9,527	137,614	267,896	10,671	16,014	12,641
Long-Term Deferred Tax Liabilities	1,072,442	1,184,420	1,214,216	487,712	449,847	470,545
Other Long-Term Liabilities	562,230	490,910	968,833	258,547	198,804	132,885
Total Liabilities	5,434,790	6,215,705	7,597,576	2,978,909	1,825,418	1,557,173
Common Stock	177,935	177,935	177,935	165,413	165,413	165,413
Additional Paid-In Capital	5,663,111	5,663,111	5,663,111	2,487,313	2,487,313	2,487,313
Retained Earnings	4,765,115	4,003,293	3,145,601	2,347,187	1,953,598	1,712,623
Comprehensive Income & Other	-14,612	-13,847	-2,173	-8,811	-7,540	-10,895
Total Common Equity	10,591,549	9,830,492	8,984,474	4,991,102	4,598,783	4,354,454
Shareholders' Equity	10,591,549	9,830,492	8,984,474	4,991,102	4,598,783	4,354,454
Total Liabilities & Equity	16,026,340	16,046,197	16,582,050	7,970,011	6,424,201	5,911,627
Total Debt	969,815	1,909,333	2,514,033	1,292,747	784,905	653,706
Net Cash (Debt)	18,296	146,943	679,504	78,688	67,147	36,217
Net Cash Growth	-	-78.37%	763.54%	17.19%	85.40%	-84.59%
Net Cash Per Share	257.06	2064.56	9733.67	1189.27	1014.84	547.37
Filing Date Shares Outstanding	71.17	71.17	71.17	66.17	66.17	66.17
Total Common Shares Outstanding	71.17	71.17	71.17	66.17	66.17	66.17
Working Capital	1,245,136	1,364,127	2,276,115	1,715,881	1,162,046	665,756
Book Value Per Share	148812.06	138119.15	126232.53	75434.17	69504.77	65812.04
Tangible Book Value	7,634,454	6,572,461	5,765,016	4,958,931	4,575,439	4,332,626
Tangible Book Value Per Share	107264.65	92343.57	80998.90	74947.94	69151.95	65482.15
Land	141,114	141,065	141,065	-	-	-
Buildings	1,955,403	1,943,694	1,376,222	832,519	792,906	791,074
Machinery	2,600,181	2,525,344	1,811,982	1,380,919	1,295,244	1,208,240
Construction In Progress	1,118,821	202,411	825,199	583,360	105,470	36,715

Source: S&P Capital IQ. Standard template. Financial Sources.